Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7820 plus cetuximab in advanced solid tumors and colorectal cancer
NCT00309179Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2007
- Primary completion
- Dec 2009
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of e7820 in colorectal cancer (CRC) and solid tumor, sponsored by Eisai Co., Ltd. Primary endpoints: Objective Response Rate at 12 weeks and Disease Control Rate at 12 weeks. Started Sep 2007; status: completed.
02
Drugs
e7820
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT00309179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309179.